A European Union-based double-blind study, placebo-controlled Phase 2 clinical trial involving ivermectin in 100 patients with mild COVID-19 recently produced results for the world. Based in the Eastern European nation of Bulgaria, the clinical trial was organized after scientists here learned of the data revealing that the drug blocks penetration of SARS-CoV-2’s transport protein into the cell nucleus and thus inhibits or hinders replication, which could possibly be of use in combating this pandemic. Led by a company called HuvePhamra, which makes the ivermectin-based product known as Huvemex®, the study involved 3mg tablets at 12 hospitals under a protocol approved by the Executive Agency for Medicines in alignment with European Union and national regulatory guidelines. Although not a large study and no material mortality rate data, this study appears to be the first completed double-blinded, placebo-controlled ivermectin study conducted in the European Union.
According to reports from Bulgarian media outlet Economic.BG, the study (EUDRACT2020-002091-12) involved recruiting and enrolling individuals with positive PCR tests and onset of symptoms no greater than 7 ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).